We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Clinical trials often struggle to recruit enough participants, with only 10% of eligible patients enrolling. This is concerning for conditions like stroke, where timely decision-making is crucial. Frontline clinicians typically screen patients manually, but this approach can be overwhelming and lead to many eligible patients being overlooked.
Methods:
To address the problem of efficient and inclusive screening for trials, we developed a matching algorithm using imaging and clinical variables gathered as part of the AcT trial (NCT03889249) to automatically screen patients by matching these variables with the trials’ inclusion and exclusion criteria using rule-based logic. We then used the algorithm to identify patients who could have been enrolled in six trials: EASI-TOC (NCT04261478), CATIS-ICAD (NCT04142125), CONVINCE (NCT02898610), TEMPO-2 (NCT02398656), ESCAPE-MEVO (NCT05151172), and ENDOLOW (NCT04167527). To evaluate our algorithm, we compared our findings to the number of enrollments achieved without using a matching algorithm. The algorithm’s performance was validated by comparing results with ground truth from a manual review of two clinicians. The algorithm’s ability to reduce screening time was assessed by comparing it with the average time used by study clinicians.
Results:
The algorithm identified more potentially eligible study candidates than the number of participants enrolled. It also showed over 90% sensitivity and specificity for all trials, and reducing screening time by over 100-fold.
Conclusions:
Automated matching algorithms can help clinicians quickly identify eligible patients and reduce resources needed for enrolment. Additionally, the algorithm can be modified for use in other trials and diseases.
Cognitive impairment, anxiety, depression, fatigue, and dependence in instrumental activities of daily living (ADL) are common after stroke; however, little is known about how these outcomes may differ following treatment with endovascular clot retrieval (ECR), intravenous tissue plasminogen activator (t-PA), or conservative management.
Methods:
Patients were recruited after acute treatment and invited to participate in an outcome assessment 90–120 days post-stroke. The assessment included a cognitive test battery and several questionnaires. The COVID-19 pandemic led to significant disruptions in recruitment and data collection, and the t-PA and conservative management groups were combined into a standard medical care (SMC) group.
Results:
Sixty-two participants were included in the study (ECR = 31, SMC = 31). Mean age was 66.5 (20–86) years, and 35 (56.5%) participants were male. Participants treated with ECR had significantly higher National Institutes of Health Stroke Scale scores at presentation and significantly lower education. After adjusting for stroke severity, premorbid intellectual ability, and age, treatment with ECR was associated with significantly better performances on measures of cognitive screening, visual working memory, and verbal learning and memory. Participants treated with ECR also experienced less fatigue and were more likely to achieve independence in basic and instrumental ADLs. Despite this, cognitive impairment and fatigue were still common among participants treated with ECR and anxiety and depression symptoms were experienced similarly by both groups.
Conclusions:
Cognitive impairment and fatigue were less common but still prevalent following treatment with ECR. This has important practical implications for stroke rehabilitation, and routine assessment of cognition, emotion, and fatigue is recommended for all stroke survivors regardless of stroke treatment and functional outcome.
Numerous studies have shown longer pre-hospital and in-hospital workflow times and poorer outcomes in women after acute ischemic stroke (AIS) in general and after endovascular treatment (EVT) in particular. We investigated sex differences in acute stroke care of EVT patients over 5 years in a comprehensive Canadian provincial registry.
Methods:
Clinical data of all AIS patients who underwent EVT between January 2017 and December 2022 in the province of Saskatchewan were captured in the Canadian OPTIMISE registry and supplemented with patient data from administrative data sources. Patient baseline characteristics, transport time metrics, and technical EVT outcomes between female and male EVT patients were compared.
Results:
Three-hundred-three patients underwent EVT between 2017 and 2022: 144 (47.5%) women and 159 (52.5%) men. Women were significantly older (median age 77.5 [interquartile range: 66–85] vs.71 [59–78], p < 0.001), while men had more intracranial internal carotid artery occlusions (48/159 [30.2%] vs. 26/142 [18.3%], p = 0.03). Last-known-well to comprehensive stroke center (CSC)-arrival time (median 232 min [interquartile range 90–432] in women vs. 230 min [90–352] in men), CSC-arrival-to-reperfusion time (median 108 min [88–149] in women vs. 102 min [77–141] in men), reperfusion status (successful reperfusion 106/142 [74.7%] in women vs. 117/158 [74.1%] in men) as well as modified Rankin score at 90 days did not differ significantly. This held true after adjusting for baseline variables in multivariable analyses.
Conclusion:
While women undergoing EVT in the province of Saskatchewan were on average older than men, they were treated just as fast and achieved similar technical and clinical outcomes compared to men.
In the United States, one stroke occurs every 40 seconds on average. Ischemic stroke is a leading cause of serious long-term disability and the fifth leading cause of death. Every year, 795,000 people experience a new or recurrent stroke. In 2018, stroke accounted for 1 of every 19 deaths. Stroke typically occurs suddenly, with symptoms of motor weakness, impaired speech, vision loss, or numbness, and can lead to significant disability. The financial burden of stroke, including direct medical costs and potential wages lost, is greater than $30 billion per year. Time-based acute stroke treatments improve functional outcome and reduce mortality, which makes rapid recognition of stroke of utmost importance.
Stroke can cause cognitive impairment, which can lead to challenges returning to day-to-day activities. Knowing what factors are associated with cognitive impairment post-stroke can be useful for predicting outcomes and guiding rehabilitation. One such factor is gender: previous studies are inconclusive as to whether gender influences cognitive outcomes post-stroke. Accounting for key variables, we examined whether there are gender differences in cognitive outcomes after stroke.
Method:
We analyzed data from neuropsychological assessments of 237 individuals tested in the chronic epoch (≥ 3 months) following ischemic stroke. Using ANCOVA and linear mixed modeling, we examined gender as a predictor of cognition as measured by general cognitive ability (g), Full-Scale IQ, and 18 cognitive tests, controlling for age at stroke onset, education, premorbid intelligence, and lesion volume.
Results:
There were no significant gender differences in overall cognitive outcomes as measured by g (p = .887) or Full-Scale IQ (p = .801). There were some significant gender differences on specific cognitive tests, with women outperforming men on scores from the Rey Auditory Verbal Learning Test (ps < .01) and men outperforming women on the Wechsler Adult Intelligence Scale Arithmetic and Information subtests (ps < .01).
Conclusions:
Our findings indicate that men and women have similar overall cognitive outcomes after stroke, when demographic and lesion factors are accounted for. Although men and women differed in their performance on some individual cognitive tests, neither gender performed systematically better or worse. However, for learning, working memory, and verbal knowledge/comprehension, gender may be an important predictor of outcome post-stroke.
Antiphospholipid antibody syndrome (APS) is a multisystem autoimmune disease characterized by venous or arterial thrombosis and/or pregnancy morbidity in the presence of persistent antiphosholipid antibodies (aPLs). Central nervous system is often affected and thrombotic or embolic ischaemic stroke (IS) is the most frequent complication. Intracranial stenosis or occlusion accounts for about 50% of APS patients, especially in the Middle cerebral artery territory (MCA). We report a case of a young woman with recurrent cerebral ischemic lesions and history of miscarriages. In 2015 a 43 years old woman was admitted to Emergency Department (ED) due to a left brachial weakness at wake-up from an ischemic fronto-parietal lesions and steno-occlusion of the proximal M1 segment of the right Middle Cerebral Artery (MCA). She had a history of arterial hypertension, migraine, previous transient ischemic attack (TIA) and was a tobacco smoker. Diagnostic workup showed high levels of aPLs. She was discharged with improved clinical conditions on antiplatelet and steroid therapy, but she had recurrent IS a month later and three years later. In the same period, she reported two miscarriages. Follow up lab tests confirmed high-titre of aPLs. Therefore, diagnosis of APS was validated. A direct oral anticoagulant was started. No recurrent events occurred over the next 2-year follow-up. Stroke is a common manifestation in APS. Diagnosis of APS is not easy. Prospective data on the therapeutic approach to APS patients with IS are scarce and recurrence rate of thrombotic events among APS patients are high, despite anticoagulation
Chagas disease (CD) is a vector-borne illness caused by the Trypanosoma cruzi parasite. It is the third most common parasitic infection worldwide and a major health problem in non-endemic regions. It can cause gastrointestinal and cardiac lesions due to cell infiltration and necrosis; common manifestations include cardiomyopathy and megaesophagus. Also, ischemic stroke is well documented, mainly due to cardioembolic etiology, although the correct management and etiological diagnosis is still challenging. Here we present a rare case of CD and ischemic stroke (IS) in a young patient, discussing the difficulties in correct diagnosis, treatment and gaps of knowledge in management and diagnosis of this neglected disease. It is important for stroke physicians to be aware of this condition, as a correct treatment, secondary prophylaxis and early referral to cardiology follow-up can potentially change drastically the natural history of the condition
Typical neuroimaging presentation of preeclampsia/eclampsia are posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS).Eclampsia carries a high risk for stroke, both hemorrhagic and ischemic. Besides eclampsia, pregnancy-specific causes of ischemic stroke are peripartum cardiomyopathy, postpartum benign angiopathy, amniotic fluid embolization and choriocarcinoma.The incidence of cerebral venous thrombosisis the highest during postpartum and is increased in older women, cesarean delivery, or epidural anesthesia, in the presence of infection, obesity or thrombophilia. Risk factors for hemorrhagic stroke during pregnancy and postpartum are older age, pregestational and gestational hypertension, preeclampsia/eclampsia, coagulopathies, and smoking
Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by intravascular coagulation activation, which can arise from different causes. The diagnosis of DIC is based on a combination of clinical features, underlying condition and laboratory testing. Neurologic manifestations of DIC result in either cerebral thromboses or bleeding. Seizures, hemiparesis, aphasia, visual field disorders are common clinical signs. In the treatment of DIC, the first step would be to treat the underlying causes and thrombotic or haemorrhagic complications. Treatment with low-molecular-weight heparin in DIC may be preferred to unfractionated heparin in DIC with thrombotic complications.Thrombotic thrombocytopenic purpura (TTP) is the most common type of thrombotic microangiopathy. Pathophysiology of the acquired TTP (Moschkowitz syndrome) is combined with an increase of Willebrand factor due to a congenital or acquired deficiency of its cleaving metalloprotease (ADAMTS13). The causes of secondary Moschkowitz syndrome can be drug-associated, pregnant and postpartum patients and those with HIV or systemic autoimmune diseases. Diagnostic pentad of clinical manifestations includes microangiopathic haemolytic anaemia, severe thrombocytopenia, fever, renal involvement and various neurologic symptoms. Brain CT or MRI usually reveals small and multiple ischemic lesions, involving different arterial territories in both anterior and posterior circulations. Plasma exchange therapy, corticosteroid therapy, and rituximab (refractory or relapsed forms of the disease) are effective in patients with TTP. Oral aspirin may be prescribed at a preventive dose range until the termination of corticosteroid use
A 53-year-old woman, with no vascular risk factors or significant previous medical history experienced first ischemic stroke and was successfully treated with thrombolysis. A thorough diagnostic work-up and long term follow up did not reveal any cardiovascular condition, the patient had been on hormone replacement therapy for 7 years at the time of the cerebrovascular accident. Effect of hormone replacement therapy and the role of other commonly prescribed drugs on the stroke burden risk are briefly discussed. Individualized therapeutic plan balancing risks, benefits, comorbidities and patients choice is recommended to reduce stroke burden especially in patients needing polytherapy
Stroke is an episode of sudden neurological dysfunction caused by focal ischemia of the central nervous system leading to cell death. Transient ischemic attack (TIA) is a transient episode of neurological dysfunction, without acute infarction. Stroke is a leading cause of long-term disability and the fifth leading cause of death in the United States. Advancing age remains a leading nonmodifiable risk factor for stroke. Targeting modifiable risk factors is critical to preventing recurrent strokes. This includes screening for diabetes, initiating statin therapy, and identifying and treating atrial fibrillation and hypertension. Aspirin remains the preferred antiplatelet drug for secondary prevention of ischemic stroke (in the absence of an indication for anticoagulation); however, patients with minor stroke or TIA should be treated for at least 21–30 days with both aspirin and clopidogrel. The management of acute ischemic stroke centers around thrombolytic treatment and mechanical thrombectomy, to maximize cerebral perfusion to the ischemic brain tissue. This must be balanced against the risks for hemorrhagic complications. Common poststroke complications include venous thromboembolic disease, dysphagia, and depression. All members of the health-care team and physicians should communicate openly and frequently with patients, their families, and/or their caregivers to ensure that their goals of care are met.
Severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease-2019, has been associated with an increased risk for ischemic and hemorrhagic stroke. As data emerge about the underlying mechanisms, it is important to synthesize current knowledge to improve effective treatment options. In this review, we highlight the known pathophysiology, discuss the relationship between ischemic and hemorrhagic stroke, and address emerging implications for patient management. The information here is compiled to be a user-friendly, quick guide to help practitioners select management options for these patients.
Patients with atrial fibrillation (AF) and ischemic stroke are at high risk for stroke recurrence. Early anticoagulation may reduce the risk of recurrent events but is usually avoided due to the risk of hemorrhagic transformation (HT). Current guidelines are based on empiric expert opinion. The assumed risk of HT is based on historical data from an older generation of anticoagulants. The direct oral anticoagulants (DOACs) have demonstrated lower risk of intracranial hemorrhage compared to older anticoagulants. However, the optimal timing of DOAC initiation after AF-related ischemic stroke has remained an area of clinical equipoise, as the pivotal phase III trials did not include patients in the early period after ischemic stroke. Multiple prospective studies and a few smaller randomized controlled trials evaluating the safety and efficacy of early versus delayed DOAC initiation have been completed. These studies have reported promising results of early DOAC initiation after acute ischemic stroke. However, a standardized documentation of HT rates on follow-up imaging with objective assessment criteria is missing from most of these studies. Larger randomized trials of early versus delayed DOAC are ongoing. A literature review was performed using keywords and Medical Subject Headings in MEDLINE/PubMed and Google Scholar databases. For each relevant paper, the bibliography was scrutinized for other relevant articles and journals. In this article, we review the risk of recurrent ischemic stroke and HT in patients with AF, pathophysiology, classification, predictors, natural history, and outcomes of HT and discuss the studies of early anticoagulation after AF-related ischemic stroke.
The superior parietal lobule (SPL) plays a strategic role in somatosensory and visuomotor integration. This study aims to evaluate the clinical, neurocognitive, and behavioral characteristics of isolated SPL stroke.
Methods
We assessed neuropsychological and behavioral findings in 14 patients with isolated SPL stroke among 4200 patients with ischemic stroke. All patients underwent neuroimaging, clinical and neuropsychological assessment after stroke.
Results:
Of the 14 patients enrolled, the first complaints were tactile and visuospatial disorders at stroke onset. Except for 6 patients with only 1 cognitive impairment, the majority of patients (57%) experienced more than 1 cognitive impairment category. Functional hemispheric asymmetries have been found in different cognitive processes, such as between visuospatial and body image functions and language process. Among visuospatial abilities disorders, spatial disorientation, visuospatial neglect, and visual extinction were found in two-thirds (63%) of patients with right SPL lesion. Body schema and image disorders were observed in all patients with right-sided lesions, such as alien hand, autotopagnosia for body parts (36%), autotopagnosia for sensory sensations (36%), and fading limb (21%). Two-thirds (57%) of patients with left SPL had impairment in language abilities.
Conclusion
Our findings after stroke suggest that SPL plays a pivotal role in the regulation of visuospatial abilities, body schema and body image processing, and language skills through bilateral frontoparietal networks and interhemispheric parietal networks.
Sex disparities have been reported across many aspects of acute ischemic stroke (AIS) care; however, there is a relative paucity of research examining sex differences in outcomes following endovascular treatment (EVT). Some studies report worse functional independence for females following EVT. Few, if any of these studies account for differences in age, baseline function, and comorbidity burden. This retrospective cohort study aimed to assess for sex differences in functional outcomes following EVT by comparing 90-day modified Rankin Scale (mRS) of males and females while controlling for baseline function and comorbidity burden.
Methods:
Baseline demographic and clinical data, and stroke severity were compared for 230 consecutive patients undergoing EVT for AIS between October 2014 and July 2019 at a tertiary stroke centre in Toronto, Canada. Effect of sex on likelihood of functional independence post-EVT was assessed using regression analysis with and without correction for age, baseline mRS, and Charlson Comorbidity Index (CCI).
Results:
Females undergoing EVT for AIS were older (75 ± 13 vs. 66 ± 15, p < 0.0001), with worse clinical and functional baselines. Unadjusted, males were more functionally independent (90-day mRS < 3) [OR = 1.831, 95%CI 1.082–3.098]. After controlling for age, baseline mRS and CCI, there was no difference between groups [OR 1.21, 95%CI 0.61–2.37].
Conclusions:
This study provides evidence that prior findings of sex disparities in function after EVT may be accounted for by differences in age, baseline clinical status and functional independence between males and females when a comprehensive measure of comorbidity burden is utilized.
To determine the association between delay in transfer to a central stroke unit from peripheral institutions and outcomes.
Methods:
We conducted a retrospective cohort study of all patients with acute stroke, admitted to a comprehensive stroke center (CSC) from three emergency departments (EDs), between 2016 and 2018. The primary outcomes were length of stay, functional status at 3 months, discharge destination, and time to stroke investigations.
Results:
One thousand four hundred thirty-five patients were included, with a mean age of 72.9 years, and 92.4% ischemic stroke; 663 (46.2%) patients were female. Each additional day of delay was associated with 2.0 days of increase in length of stay (95% confidence interval [CI] 0.8–3.2, p = 0.001), 11.5 h of delay to vascular imaging (95% CI 9.6–13.4, p < 0.0001), 24.2 h of delay to Holter monitoring (95% CI 7.9–40.6, p = 0.004), and reduced odds of nondisabled functional status at 3 months (odds ratio 0.98, 95% CI 0.96–1.00, p = 0.01). Factors affecting delay included stroke onset within 6 h of ED arrival (605.9 min decrease in delay, 95% CI 407.9–803.9, p < 0.0001), delay to brain imaging (59.4 min increase in delay for each additional hour, 95% CI 48.0–71.4, p < 0.0001), admission from an alternative service (3918.7 min increase in delay, 95% CI 3621.2–4079.9, p < 0.0001), and transfer from a primary stroke center (PSC; 740.2 min increase in delay, 95% CI 456.2–1019.9, p < 0.0001).
Conclusion:
Delay to stroke unit admission in a system involving transfer from PSCs to a CSC was associated with longer hospital stay and poorer functional outcomes.